Evoli A - Search Results

1

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ. Guptill JT, et al. Among authors: evoli a. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 25745635 Free PMC article.

2

Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement.

Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, Bartoccioni E. Scuderi F, et al. Among authors: evoli a. Lab Invest. 2002 Sep;82(9):1139-46. doi: 10.1097/01.lab.0000028144.48023.9b. Lab Invest. 2002. PMID: 12218074 Free article.

3

Response to therapy in myasthenia gravis with anti-MuSK antibodies.

Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E. Evoli A, et al. Ann N Y Acad Sci. 2008;1132:76-83. doi: 10.1196/annals.1405.012. Ann N Y Acad Sci. 2008. PMID: 18567856 Clinical Trial.

4

Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis.

Provenzano C, Marino M, Scuderi F, Evoli A, Bartoccioni E. Provenzano C, et al. Among authors: evoli a. J Neuroimmunol. 2010 Jan 25;218(1-2):102-6. doi: 10.1016/j.jneuroim.2009.11.004. Epub 2009 Nov 26. J Neuroimmunol. 2010. PMID: 19942297

5

Immunosuppressive therapies in myasthenia gravis.

Sanders DB, Evoli A. Sanders DB, et al. Among authors: evoli a. Autoimmunity. 2010 Aug;43(5-6):428-35. doi: 10.3109/08916930903518107. Autoimmunity. 2010. PMID: 20166870 Free article. Review.

6

BAFF serum levels in myasthenia gravis: effects of therapy.

Scuderi F, Alboini PE, Bartoccioni E, Evoli A. Scuderi F, et al. Among authors: evoli a. J Neurol. 2011 Dec;258(12):2284-5. doi: 10.1007/s00415-011-6092-z. Epub 2011 May 11. J Neurol. 2011. PMID: 21559937 No abstract available.

7

Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.

Guptill JT, Sanders DB, Evoli A. Guptill JT, et al. Among authors: evoli a. Muscle Nerve. 2011 Jul;44(1):36-40. doi: 10.1002/mus.22006. Muscle Nerve. 2011. PMID: 21674519

8

PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.

Provenzano C, Ricciardi R, Scuderi F, Maiuri MT, Maestri M, La Carpia F, Sferrazza A, Marino M, Leone L, Lucchi M, Mussi A, Zollino M, Evoli A, Bartoccioni E. Provenzano C, et al. Among authors: evoli a. Neuromuscul Disord. 2012 Feb;22(2):131-8. doi: 10.1016/j.nmd.2011.09.003. Epub 2011 Dec 24. Neuromuscul Disord. 2012. PMID: 22197427

9

Management challenges in muscle-specific tyrosine kinase myasthenia gravis.

Evoli A, Alboini PE, Bisonni A, Mastrorosa A, Bartoccioni E. Evoli A, et al. Ann N Y Acad Sci. 2012 Dec;1274:86-91. doi: 10.1111/j.1749-6632.2012.06781.x. Ann N Y Acad Sci. 2012. PMID: 23252901

10

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A. Catzola V, et al. Among authors: evoli a. J Neurol. 2013 Aug;260(8):2163-5. doi: 10.1007/s00415-013-6987-y. Epub 2013 Jun 8. J Neurol. 2013. PMID: 23749295 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters